{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["28(4)"],"submitter":["Behrens G"],"pubmed_abstract":["The once daily, single-tablet regimen (STR) combining rilpivirine (RPV), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) provides a simplified treatment option for antiretroviral therapy (ART)-naïve patients with baseline HIV-1 RNA (BLVL) of ≤100,000 copies/mL. The aim of this analysis is to compare long-term efficacy, safety, and tolerability of RPV+FTC/TDF vs. efavirenz (EFV)+FTC/TDF as individual components in subjects with BLVL ≤100,000 copies/mL. Week 96 efficacy and safety data from subjects with BLVL ≤100,000 copies/mL, who received daily RPV 25 mg or EFV 600 mg with FTC/TDF in the phase 3, randomized, double-blind, double-dummy, active-controlled, registrational trials ECHO and THRIVE, were analyzed. Virologic response was evaluated by intent-to-treat, time to loss of "],"journal":["AIDS patient care and STDs"],"pagination":["168-75"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3985528"],"repository":["biostudies-literature"],"pubmed_title":["Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis."],"pmcid":["PMC3985528"],"pubmed_authors":["White K","Vanveggel S","Rimsky L","Chuck SK","Elion RA","Mills A","Stevens M","Behrens G","Bosse M","Nelson M","Rijnders B","Orkin C","DeMorin J","Cohen C","Zhong L","Thorpe D"],"additional_accession":[]},"is_claimable":false,"name":"Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.","description":"The once daily, single-tablet regimen (STR) combining rilpivirine (RPV), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) provides a simplified treatment option for antiretroviral therapy (ART)-naïve patients with baseline HIV-1 RNA (BLVL) of ≤100,000 copies/mL. The aim of this analysis is to compare long-term efficacy, safety, and tolerability of RPV+FTC/TDF vs. efavirenz (EFV)+FTC/TDF as individual components in subjects with BLVL ≤100,000 copies/mL. Week 96 efficacy and safety data from subjects with BLVL ≤100,000 copies/mL, who received daily RPV 25 mg or EFV 600 mg with FTC/TDF in the phase 3, randomized, double-blind, double-dummy, active-controlled, registrational trials ECHO and THRIVE, were analyzed. Virologic response was evaluated by intent-to-treat, time to loss of ","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Apr","modification":"2025-05-29T19:43:47.342Z","creation":"2025-05-29T19:43:47.342Z"},"accession":"S-EPMC3985528","cross_references":{"pubmed":["24660840"],"doi":["10.1089/apc.2013.0310"]}}